Influenza is a worldwide public health problem. Although current influenza vaccines are effective in battling closely matched viruses, major limitations of current vaccines are the need to produce new vaccines every season, the uncertainty in choice of the correct strains, and the inability to prevent a new influenza pandemic. Improved vaccines inducing broadly protective immune responses against multiple type A influenza viruses are urgently needed, not only for seasonal influenza but also for pandemic influenza prevention. Conserved epitopes are potent immunogens for such vaccines. Combined strategies including improved antigens, new antigen delivery techniques and vaccination regimens should be considered together to overcome current obstacles in the development of a universal influenza vaccine. In the project we propose to generate constructs encoding conserved influenza antigens which are not usually sensed the by host immune system in natural viral infection and seasonal vaccination. We will use the newest nanotechnology approach to produce nanoclusters self-assembled directly from the resulting antigenic proteins as universal influenza vaccine candidates. We will investigate the breadth of cross-protection induced by these nanovaccines in mouse and guinea pig models, and the immune correlate of the cross protection. The three specific aims to be investigated are: 1. Generation of constructs expressing conformation-stabilized HA stalk domain (csHA-stalk) and tetrameric M2e tandem repeat (tM2et) recombinant proteins. The relatively conserved stalk domain in HA is shielded by its globular head domain in virions and is less effectively sensed by immune cells. A csHA-stalk without the globular head will overcome this limitation, and retain its native conformation. Also, tM2et will retain the tetrameric structure of M2e with increased epitope density. 2. Production of nanoclusters self-assembled from csHA-stalk and tM2e antigens. These nano-size particles will be directly self-assembled from the resulting antigenic recombinant proteins, and release intact antigens after uptake. These particles will maximize antigenic payload, control spatial antigen presentation, and regulate release in DCs. We will characterize the size of the particles, antigen content, distribution and release, and internalization by DCs. 3. Investigation of immune responses and the breadth of protective immunity induced by the above nanoclusters and of immune correlates of broad cross-protection. Vaccines based on a combination of HA stalk domains from the two phylogenetic groups may protect against all influenza A viruses. The addition of tM2et will further increase the potential for broad protection. We will study immune responses induced by different nanovaccine combinations, the cross protection to challenge by a panel of influenza A viral strains, and immune correlates of the cross protection.

Public Health Relevance

Although current influenza vaccines are effective in battling closely matched viruses, the limitations include: the need to produce new vaccines every season, the uncertainty in choosing the correct strains, and the inability to prevent a new influenza pandemic. This project will develop universal influenza vaccines to overcome these limitations by inducing broad cross protection against all influenza A viruses.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Salomon, Rachelle
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgia State University
Organized Research Units
United States
Zip Code
Zhu, Wandi; Li, Song; Wang, Chao et al. (2018) Enhanced Immune Responses Conferring Cross-Protection by Skin Vaccination With a Tri-Component Influenza Vaccine Using a Microneedle Patch. Front Immunol 9:1705
Luo, Yuan; Mohan, Teena; Zhu, Wandi et al. (2018) Sequential Immunizations with heterosubtypic virus-like particles elicit cross protection against divergent influenza A viruses in mice. Sci Rep 8:4577
Wang, Ye; Deng, Lei; Kang, Sang-Moo et al. (2018) Universal influenza vaccines: from viruses to nanoparticles. Expert Rev Vaccines 17:967-976
Deng, Lei; Chang, Timothy Z; Wang, Ye et al. (2018) Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice. Proc Natl Acad Sci U S A 115:E7758-E7767
Mohan, Teena; Zhu, Wandi; Wang, Ye et al. (2018) Applications of chemokines as adjuvants for vaccine immunotherapy. Immunobiology 223:477-485
Deng, Lei; Wang, Bao-Zhong (2018) A Perspective on Nanoparticle Universal Influenza Vaccines. ACS Infect Dis :
Wang, Chao; Zhu, Wandi; Luo, Yuan et al. (2018) Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity. Nanomedicine 14:1349-1360
Deng, Lei; Mohan, Teena; Chang, Timothy Z et al. (2018) Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. Nat Commun 9:359
Zhu, Wandi; Pewin, Winston; Wang, Chao et al. (2017) A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines. J Control Release 261:1-9
Chang, Timothy Z; Stadmiller, Samantha S; Staskevicius, Erika et al. (2017) Effects of ovalbumin protein nanoparticle vaccine size and coating on dendritic cell processing. Biomater Sci 5:223-233

Showing the most recent 10 out of 23 publications